Home / Market News / $AXSM
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Morgan Stanley Adjusts Price Target for Axsome Therapeutics

Nov 13, 2026, 12:34 PM UTC · Primary ticker $AXSM

Morgan Stanley has lowered its price target for Axsome Therapeutics from $249 to $223. This adjustment reflects a revised financial outlook from the firm, which could lead to short-term negative sentiment for Axsome's stock.

Morgan Stanley, a prominent investment bank, has reduced its price target for Axsome Therapeutics (AXSM) from $249 to $223. This revision indicates a less optimistic outlook on the company's future financial performance or market valuation by the analyst. For traders, this could signal a potential short-term negative pressure on AXSM's stock price as investors react to the lowered valuation. While not a direct operational change for Axsome, a reduced price target from a major firm can influence investor sentiment and potentially lead to selling pressure, especially for those who follow analyst ratings. The long-term implications depend on whether this revised outlook is a precursor to broader market sentiment shifts or specific company developments.

$AXSM negative Price target lowered by major investment bank
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.